Halozyme Therapeutics (HALO)
(Delayed Data from NSDQ)
$42.01 USD
+0.80 (1.94%)
Updated May 8, 2024 04:00 PM ET
After-Market: $41.97 -0.04 (-0.10%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth D Momentum B VGM
Brokerage Reports
Halozyme Therapeutics, Inc. [HALO]
Reports for Purchase
Showing records 161 - 180 ( 182 total )
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
February 2012 Potential Catalysts & Milestones - Monthly Update
Provider: WEDBUSH SECURITIES INC.
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of January 22
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
LIFE SCIENCES: 2012 Life Sciences and Healthcare Preview: Macro and Sector Trends; Catalysts; Top Picks
Provider: WEDBUSH SECURITIES INC.
Analyst: JAMES S
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Positive Phase II Data for Cinryze in Combination With rHuPH20 - Insulin Pump Data Expected Q1:12
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
December 2011 Potential Milestones & Key Events - Monthly Update
Provider: WEDBUSH SECURITIES INC.
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Expert Call Highlights - HALO''s Hylenex Insulin Pump Opportunity "A Game Changer
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Adding to Best Ideas List; Insulin Opportunity Under the Radar and Undervalued
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Positive Phase II Diabetes Data Could Provide Partnership and Upside, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Positive Phase III Data for SC Herceptin - Increasing Price Target to $14 from $10 per Share; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology/Biopharmaceuticals/BioDefense: October 2011 Potential Milestones & Key Events - Monthly Update.
Provider: WEDBUSH SECURITIES INC.
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Reports Positive Phase I Data for Aspart-PH20 Trial at ADA
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
HIGHLIGHTS FOR JUNE 27, 2011
Provider: WEDBUSH SECURITIES INC.
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2011 Potential Milestones & Key Events - February Updates
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Hosts Analyst Meeting; Clarifies Development Strategy
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Phase II Study Data Examining Insulin Analogs with and without PH20 Presented at ADA Meeting.
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Life Sciences: Biopharmaceuticals / Biotechnology.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L